Locations:
Search IconSearch
April 17, 2019/Neurosciences/Research

Prescribing Limits Drive Down Opioid Exposure After Spine Surgery Without Harming Outcomes

Cleveland Clinic study assesses effects of state-level reforms

19-NEU-217-opioids-650x450pxl

Discharge prescribing of opioids after decompressive lumbar spine surgery decreased significantly without any harm detected in global health outcomes among patients at Cleveland Clinic in the year following implementation of state-level opioid prescribing reform. So finds a retrospective review presented this week at the 2019 annual scientific meeting of the American Association of Neurological Surgeons.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Our study clearly showed two things occurred as a result of new state restrictions on opioid prescribing,” says Michael Steinmetz, MD, Chair of Cleveland Clinic’s Department of Neurosurgery and senior author of the study. “First, prescribing behavior on the part of physicians changed. Second, patients were no worse for it.”

Legislative backdrop

On Aug. 31, 2017, the state of Ohio implemented new rules for prescribing opioids to treat acute pain. The rules include a limit on prescriptions to a maximum of seven days for adults and a requirement that the total morphine equivalent dose (MED) of a prescription may not exceed an average of 30 MED per day.

This posed a dramatic change to standard practice: Previously, surgeons routinely prescribed at least a two-week course of opioids at discharge, and it was not unusual to prescribe 90 days of medications to cover the expected postoperative recovery period.

“Despite widespread adoption of similar restrictions by states across the nation, little research has been done on whether such restrictions have made a difference in prescribing practices or patient outcomes,” Dr. Steinmetz notes.

Study design and findings

The study evaluated 1,098 patients who underwent a one- or two-level lumbar laminectomy at Cleveland Clinic during either the 12 months preceding the state-mandated change or the 12 months after.

The researchers found that patients in the year after reform received, on average, a MED total during the 90 days following discharge that was 174 MED lower (95% CI: –261 to –91) than the average for patients in the year prior to reform. No differences were found in the number of opioid prescriptions written, so the decline can be attributed to shorter prescription courses.

Advertisement

The patients also were evaluated postoperatively with the PROMIS-Global Health instrument, a patient-reported assessment of general physical, mental and social health. No difference in scores was found between the pre-reform and post-reform patients.

Implications

Dr. Steinmetz says this is the first study he’s aware of that evaluated changes in opioid prescribing and health outcomes from a hospital database following state-level restrictions on opioid prescribing.

He notes that it would be interesting to see if the reforms also led to reductions in overdose calls or deaths from opioids — although finding that out would require analyzing statewide data.

“This study suggests that state-level reforms placing reasonable limits on opioid prescriptions for acute pain may reduce patients’ opioid exposure without compromising patient-reported outcomes after spine surgery,” he says.

He adds that the implications go beyond the effects on individual patients, noting that patients may limit their use of pain medications and leave the remaining pills in their medicine cabinet, where they can be stolen by friends, relatives or even burglars — for their own use or for sale on the street.

“People just don’t need that much pain medication, even following surgery,” Dr. Steinmetz concludes. “This and similar reforms in other states appear to be excellent public health measures with no discernable downside.”

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad